4 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 4 Phase 2, 4 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 4 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow OM Pharma SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OM 85 to Prevent Respiratory Infections in Older At Risk Patients Bacterial Lysate, Placebo - Respiratory Tract Infections (RTI) | Phase 4 | Recruiting | Campus Bio-Medico University | 360 | 2025-02-01 | 2025-03-18 |
| OM 85 to Prevent Respiratory Infections in Older At Risk Patients Bacterial Lysate, Placebo - Respiratory Tract Infections (RTI) | Phase 4 | Active not recruiting | Fondazione Policlinico Universitario Campus Bio-Medico | 360 | 2024-12-19 | 2025-09-17 |
| A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients OM-85-IN, Placebo - Allergic Asthma | Phase 1 | Completed | OM Pharma SA | 41 | 2024-06-14 | 2025-03-03 |
| The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome OM-89 [Uro-Vaxom® Capsule], OM-89 Placebo [Uro-Vaxom® Capsule Placebo] - Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Chronic Prostatitis | Phase 4 | Unknown | AJU Pharm Co., Ltd. | 332 | 2023-12-20 | 2024-04-04 |
| A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing OM-85, Placebo - Recurrent Wheezing, Wheezing Lower Respiratory Illness | Phase 2 | Completed | OM Pharma SA | 296 | 2023-06-20 | 2026-10-16 |
| OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness OM-85, Placebo - Respiratory Tract Infections, Wheezing Lower Respiratory Illness | Phase 4 | Completed | OM Pharma SA | 525 | 2022-12-12 | 2026-09-25 |
| Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. Calcium Dobesilate, Mannitol - COVID-19 Virus Disease | Phase 2 | Completed | Hervé SPECHBACH | 74 | 2022-05-17 | 2024-02-28 |
| Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD Broncho-Vaxom, Placebo - Atopic Dermatitis | Phase 2 | Terminated | OM Pharma SA | 63 | 2021-12-20 | 2023-08-08 |
| Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD) Azithromycin, Metronidazole, Standard of Care - Crohn Disease, Pediatric Crohns Disease | Phase 2 | Terminated | University of North Carolina, Chapel Hill | 13 | 2021-08-13 | 2025-06-29 |
Respiratory Tract Infections (3) · COVID-19 (1) · Crohn Disease (1) · Dermatitis, Atopic (1) · Lymphoma, Follicular (1) · Prostatitis (1) · Respiratory Sounds (1)
Broncho-Vaxom (3) · Azithromycin (1) · Calcium Dobesilate (1) · Mannitol (1) · Metronidazole (1) · OM 89 (1) · Standard of Care (1)
Germany (3) · Italy (3) · Poland (3) · Hungary (2) · Netherlands (2) · Switzerland (2) · United States (2) · Australia (1) · Canada (1) · France (1) · Israel (1) · South Korea (1) · United Kingdom (1)
Arie Levine, MD (1) · Francisco Sylvester, MD (1) · Franziska Rueff, Professor (1) · Johan E Van Limbergen, MD, PhD (1)